Pembolizumab

DRUG4 trials

Sponsors

Shanghai JMT-Bio Inc., Gruppo Oncologico del Nord-Ovest, Glycyx Therapeutics

Conditions

HER2-positive Gastric CancerHead & Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Phase 1

A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer

Not yet recruitingNCT07662720

Glycyx TherapeuticsHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Start: 2026-07-15End: 2028-08-31Target: 18Updated: 2026-07-15

Phase 2

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Not yet recruitingNCT06998771

Shanghai JMT-Bio Inc.HER2-positive Gastric Cancer

Start: 2025-06-15End: 2029-12-31Target: 153Updated: 2025-05-31

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Not yet recruitingNCT07332533

Shanghai JMT-Bio Inc.HER2-positive Gastric Cancer

Start: 2025-12-30End: 2032-12-31Target: 490Updated: 2026-01-12

Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

RecruitingNCT07485296

Gruppo Oncologico del Nord-OvestHead & Neck Squamous Cell Carcinoma

Start: 2026-01-27End: 2032-12-01Target: 45Updated: 2026-03-20